跳轉至內容
Merck
全部照片(1)

Key Documents

V-006

Supelco

丙戊酸标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C8H16O2
CAS號碼:
分子量::
144.21
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

品質等級

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

格式

single component solution

儲存溫度

−20°C

SMILES 字串

CCCC(CCC)C(O)=O

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

InChI 密鑰

NIJJYAXOARWZEE-UHFFFAOYSA-N

基因資訊

human ... ALDH5A1(7915)

一般說明

经认证的加标溶液®适用于临床毒理学、法医分析、尿液药物检测、处方监测或药物研究中的LC/MS或GC/MS应用。丙戊酸是一种抗癫痫药和情绪稳定剂,以Depakote®,Valparin或Stavzor®等商品名出售。该药物被处方用于治疗癫痫、躁郁症、偏头痛和抑郁症。

應用


  • The prenatal use of agmatine prevents social behavior deficits in VPA-exposed mice by activating the ERK/CREB/BDNF signaling pathway: This study explores the neuroprotective effects of agmatine against Valproic acid-induced behavioral deficits in mice, highlighting Valproic acid′s role in epigenetic modifications and its potential use in developmental neurotoxicology research (Chen et al., 2024).


法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Depakote is a registered trademark of Sanofi S.A.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Stavzor is a registered trademark of Noven Therapeutics, LLC

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Emily C Bell et al.
Human psychopharmacology, 20(6), 415-424 (2005-08-18)
Previous functional imaging studies have shown altered brain activity during cognitive task performance in bipolar patients. However, the fact that these patients are often on medication makes it unclear to what extent these changes reflect treatment effects. This study aims
Wolfgang Löscher
CNS drugs, 16(10), 669-694 (2002-09-25)
Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has become established worldwide as one of the most widely used AEDs in the treatment of both generalised and partial seizures in adults and children.
Heath R Pardoe et al.
Neurology, 80(20), 1895-1900 (2013-04-26)
We hypothesized that total brain volume, white matter volume, and lobar cortical thickness would be different in epilepsy patients. We studied valproate relative to nonvalproate by using patients with epilepsy and healthy controls. Patients with focal intractable epilepsy from a
S Eyal et al.
British journal of pharmacology, 149(3), 250-260 (2006-08-09)
The antiepileptic drug valproic acid, a histone deacetylase (HDAC) inhibitor, is currently being tested as an anticancer agent. However, HDAC inhibitors may interact with anticancer drugs through induction of P-glycoprotein (P-gp, MDR1) expression. In this study we assessed whether valproic
Matthew D Sztajnkrycer
Journal of toxicology. Clinical toxicology, 40(6), 789-801 (2002-12-12)
Acute valproic acid intoxication is an increasing problem, accounting for more than 5000 calls to the American Association of Poison Control Centers in 2000. The purpose of this paper is to review the pharmacology and toxicology of valproic acid toxicity.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務